Skip to main content

Table 1 General characteristics, clinical preoperative data, and preoperative medication

From: Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study

 Terlipressin group (n = 50)Placebo group (n = 50)P value
Age (years)55.8 ± 6.054.4 ± 5.60.26
Gender (M/F) (n)40/1043/70.44
Weight (kg)71.8 ± 7.374.0 ± 8.60.17
Height (cm)160.5 ± 5.7158.6 ± 6.30.10
Ejection Fraction52.8 ± 8.050.6 ± 6.90.14
Euro score II1.1 ± 0.41.2 ± 0.30.36
Hypertension (n)33280.32
Diabetes mellitus (n)21260.42
Left main disease (n)10130.64
No. of diseased coronaries (2/3)20/3017/330.54
Losartan dose (mg/d)52 ± 26.653.5 ± 32.30.80
β-blocker (n)43460.36
Calcium channel blocker (n)750.76
Nitrate (n)40420.61
Diuretic (n)9110.63
  1. n number of patients, M/F male to female ratio
  2. Mean ± SD
  3. P value is significant when P < 0.05
\